Advancements in Gastroenterology: A Weekly Review
Gastroenterologia
Gastroenterology Updates: From Peptic Ulcers to Fecal Incontinence
This week's episode covers updated peptic ulcer guidelines, endoscopic sedation protocols, advances in IBD treatment, pediatric celiac screening, innovative fecal incontinence therapy, and plant-based IBS approaches.
Accedi o Registrati per ascoltare questo episodio
Bibliografia
1. Evidence-based clinical practice guidelines for peptic ulcer disease 2026.
Authors: Sugimoto M, Kamada T, Ito M, et al.
Journal: Journal of gastroenterology, 2026 Oct
PMID: 42635735
DOI: 10.1007/s00535-026-02504-3
2. Sedation for gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastroenterology and Endoscopy Nurses and Associates (ESGENA) Guideline.
Authors: Triantafyllou K, Tziatzios G, Tham TC, et al.
Journal: Endoscopy, 2026 Oct
PMID: 42480549
DOI: 10.1055/a-2898-6540
3. Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study.
Authors: Scaldaferri F, Di Vincenzo F, Aloi M, et al.
Journal: The American journal of gastroenterology, 2026 Oct 1
PMID: 41705712
DOI: 10.14309/ajg.0000000000003969
4. Screening for Celiac Disease in Children: Practical Guidance for Primary Care Providers.
Authors: Baranwal P
Journal: Rhode Island medical journal (2013), 2026 Oct 1
PMID: 42789810
5. Crohn's disease, vedolizumab and autoinmmune hemolytic anemia: coincidence or causality?
Authors: Alvarado Jara R, Pérez Calle JL, Igualada Escribano L, et al.
Journal: Revista espanola de enfermedades digestivas, 2026 Oct
PMID: 41848075
DOI: 10.17235/reed.2026.11879/2026
6. Randomized Sham-Controlled Trial of Translumbosacral Neuromodulation Therapy for Fecal Incontinence.
Authors: Rao SSC, Yan Y, Hamdy S, et al.
Journal: Gastroenterology, 2026 Oct
PMID: 42105947
DOI: 10.1053/j.gastro.2026.04.027
7. Systematic Review and Meta-Analysis: Plant-Based Therapy for Irritable Bowel Syndrome.
Authors: Meyer A, Auer J, Cascant-Ortolano L, et al.
Journal: Phytotherapy research : PTR, 2026 Oct
PMID: 42572206
DOI: 10.1002/ptr.70421
8. Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction-Associated Steatohepatitis-Reanalysis of Fibrosis Stage 2-3 Subset.
Authors: Mironova M, Padmanabhan K, Schneider D, et al.
Journal: Alimentary pharmacology & therapeutics, 2026 Oct
PMID: 42527732
DOI: 10.1111/apt.70888
9. Tumor-Infiltrating Lymphocytes as a Predictor of Adjuvant Avelumab Efficacy in Patients with High-risk Triple-Negative Breast Cancer.
Authors: Dieci MV, Gasparini E, Nicolé L, et al.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research, 2026 Oct 1
PMID: 42467210
DOI: 10.1158/1078-0432.CCR-26-0975
10. Efficacy and safety of probiotic supplementation in PsA-a randomized controlled trial.
Authors: Bosch P, Lackner A, Dreo B, et al.
Journal: Rheumatology (Oxford, England), 2026 Oct 1
PMID: 42832303
DOI: 10.1093/rheumatology/keag547
Authors: Sugimoto M, Kamada T, Ito M, et al.
Journal: Journal of gastroenterology, 2026 Oct
PMID: 42635735
DOI: 10.1007/s00535-026-02504-3
2. Sedation for gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastroenterology and Endoscopy Nurses and Associates (ESGENA) Guideline.
Authors: Triantafyllou K, Tziatzios G, Tham TC, et al.
Journal: Endoscopy, 2026 Oct
PMID: 42480549
DOI: 10.1055/a-2898-6540
3. Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study.
Authors: Scaldaferri F, Di Vincenzo F, Aloi M, et al.
Journal: The American journal of gastroenterology, 2026 Oct 1
PMID: 41705712
DOI: 10.14309/ajg.0000000000003969
4. Screening for Celiac Disease in Children: Practical Guidance for Primary Care Providers.
Authors: Baranwal P
Journal: Rhode Island medical journal (2013), 2026 Oct 1
PMID: 42789810
5. Crohn's disease, vedolizumab and autoinmmune hemolytic anemia: coincidence or causality?
Authors: Alvarado Jara R, Pérez Calle JL, Igualada Escribano L, et al.
Journal: Revista espanola de enfermedades digestivas, 2026 Oct
PMID: 41848075
DOI: 10.17235/reed.2026.11879/2026
6. Randomized Sham-Controlled Trial of Translumbosacral Neuromodulation Therapy for Fecal Incontinence.
Authors: Rao SSC, Yan Y, Hamdy S, et al.
Journal: Gastroenterology, 2026 Oct
PMID: 42105947
DOI: 10.1053/j.gastro.2026.04.027
7. Systematic Review and Meta-Analysis: Plant-Based Therapy for Irritable Bowel Syndrome.
Authors: Meyer A, Auer J, Cascant-Ortolano L, et al.
Journal: Phytotherapy research : PTR, 2026 Oct
PMID: 42572206
DOI: 10.1002/ptr.70421
8. Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction-Associated Steatohepatitis-Reanalysis of Fibrosis Stage 2-3 Subset.
Authors: Mironova M, Padmanabhan K, Schneider D, et al.
Journal: Alimentary pharmacology & therapeutics, 2026 Oct
PMID: 42527732
DOI: 10.1111/apt.70888
9. Tumor-Infiltrating Lymphocytes as a Predictor of Adjuvant Avelumab Efficacy in Patients with High-risk Triple-Negative Breast Cancer.
Authors: Dieci MV, Gasparini E, Nicolé L, et al.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research, 2026 Oct 1
PMID: 42467210
DOI: 10.1158/1078-0432.CCR-26-0975
10. Efficacy and safety of probiotic supplementation in PsA-a randomized controlled trial.
Authors: Bosch P, Lackner A, Dreo B, et al.
Journal: Rheumatology (Oxford, England), 2026 Oct 1
PMID: 42832303
DOI: 10.1093/rheumatology/keag547
